Clinical and Experimental Pediatrics

Search

Search

Close


Warning: fopen(/home/virtual/pediatrics/journal/upload/ip_log/ip_log_2024-11.txt) [function.fopen]: failed to open stream: Permission denied in /home/virtual/pediatrics/journal/ip_info/view_data.php on line 93

Warning: fwrite(): supplied argument is not a valid stream resource in /home/virtual/pediatrics/journal/ip_info/view_data.php on line 94

All issues > Volume 45(4); 2002

Original Article
J Korean Pediatr Soc. 2002;45(4):439-448. Published online April 15, 2002.
Therapeutic Effect of Different Doses of Recombinant Human Granulocyte Colony-Stimulating Factor(rhG-CSF) on Neonatal Sepsis Complicated by Neutropenia
Moon Young MY Choi1, Yeon Sook YS Jung1, Dong Woo DW Son2, Hyo Seop HS Ahn3
1Department of Pediatrics, Eulji Hospital, Seoul, Korea
2Department of Pediatrics, Bombit Hospital, Seoul, Korea
3Department of Pediatrics, College of Medicine, Seoul National University, Seoul, Korea
Correspondence Moon Young MY Choi ,Email: mrkorila@hanmail.net
Abstract
Purpose
: The aim of this study is to determine and compare the effects of adjunctive therapy with different doses of recombinant human granulocyte-colony stimulating factor(rhG-CSF) on reversing sepsis-associated neonatal neutropenia, and their survival rate in a group I/II-type trial.
Methods
: RhG-CSF was injected subcutaneously to 10 septic-neutropenic neonates with doses of 10 μg/kg from Oct. 1995 to Sep. 1996, and was administered to another 12 septic-neutropenic neonates with doses of 5 μg/kg from Oct. 1996 to Sep. 1997. Neutrophilic responses and the outcomes of both groups were compared.
Results
: In the rhG-CSF 10 μg/kg treated group and in the 5 μg/kg treated group, the absolute neutrophil count(ANC) was 1,065±89(mean±SEM) and 1,053±131, respectively. The only difference between the two groups was the peak ANC at 48 hours. Eight patients from the remaining nine of rhG-CSF 10 μg/kg treated group(88.9%) and ten in 5 μg/kg treated group(83.3%) survived the sepsis and were discharged without any problems.
Conclusion
: RhG-CSF can increase the neutrophil count in critically ill septic neutropenic neonats. The survival rate of both groups were up to 90%. This finding suggests that both doses of rhG-CSF may be effective in a therapeutically useful time frame to treat septic neonates with neonatal neutropenia attributable to bone marrow supression or neutrophil consumption.

Keywords :Neonatal sepsis, Recombinant human granulocyte colony stimulating factor Neutropenia

Go to Top